Rate My Professor Alicja Copik

Copik's innovations have progressed to clinical trials for adult leukemia treatment and collaborations with institutions like Nationwide Children’s Hospital. She received an $800,000 grant from the Florida Department of Health’s James and Esther King Biomedical Research Program in 2019 to advance NK cell combinations with PD-L1 inhibitors for lung cancer, and a $100,000 award from the Florida Breast Cancer Foundation in 2024 for breast cancer therapies. Her PM21 particle technology founded CytoSen Therapeutics, acquired in a potentially record-breaking deal in 2019. Key publications encompass "Natural killer cells stimulated with PM21 particles expand and distribute in mice with potential for clinical applications" (Cytotherapy, 2016), "PD-L1 blockade enhances anti-tumor efficacy of NK cells" (OncoImmunology, 2018), "Oncolytic parainfluenza virus combines with NK cells to mediate systemic antitumor immunity" (Journal for ImmunoTherapy of Cancer, 2021), and "PM21-particle stimulation augmented with cytokines enhances NK cell cytotoxicity" (Frontiers in Immunology, 2024). As a core scientist at Lake Nona, she oversees flow cytometry resources and graduate program faculty contributions, impacting NK cell research and clinical translation in medicine.